<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689169</url>
  </required_header>
  <id_info>
    <org_study_id>ZBEAM2</org_study_id>
    <secondary_id>2007-000270-23</secondary_id>
    <nct_id>NCT00689169</nct_id>
  </id_info>
  <brief_title>Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma</brief_title>
  <acronym>ZBEAM2</acronym>
  <official_title>Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transplantation (ASCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of a preparative regimen
      utilizing standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy combined
      with high-dose BEAM followed by ASCT after first line treatment in patients aged from 18 to
      65 years with poor prognosis CD 20 Diffuse Large B-Cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS): events being death from any cause, relapse for complete responders and unconfirmed complete responders, progression during and after treatment and changes of therapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) (Complete Response CR and Partial Response PR)</measure>
    <time_frame>100 days</time_frame>
    <description>100 days after ASCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Lymphoma, Large Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)</intervention_name>
    <description>Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ASCT</intervention_name>
    <description>ASCT : D0</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 250 mg/m² :D-21 D-14</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged from 18 to 65 years.

          -  Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO
             classification) :

          -  Diffuse large B cell lymphoma.

          -  Adverse prognostic factors IPI&gt;1

          -  In Complete Remission, or partial response to first line treatment.

          -  Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP

          -  Chemo-sensitive disease

          -  PET Scan prior transplant

          -  Eligible for autologous stem cell transplantation

          -  With a minimum life expectancy of 3 months.

          -  Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  Histological transformation in diffuse large B cell lymphoma, any type of low grade
             lymphoma

          -  More than one line of treatment. Prior transplantation. Prior exposure to Zevalin

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contraindication to any drug contained in the chemotherapy regimen.

          -  Any serious active disease or co-morbid medical condition (according to the
             investigator's decision and information provided in the IDB).

          -  Poor renal function (creatinin level up to 2.5 maximum normal level) unless these
             abnormalities are related to the lymphoma.

          -  Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to
             2.5 maximum normal level) unless these abnormalities are related to the lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less
             than 100 G/l

          -  Large bone marrow irradiation more than 40percent.

          -  Bone marrow infiltration

          -  Lack of sufficient autologous hematopoietic stem cells for transplantation.

          -  Prior treatment with murine antibodies

          -  Known hypersensibility to murine antibodies or proteins

          -  Any history of cancer during the last 5 years, with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Adult patient unable to give informed consent because of intellectual impairment.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Gisselbrecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Fruchart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>service d'onco hématologie adultes, hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):1905-11. doi: 10.1016/j.bbmt.2014.07.024. Epub 2014 Jul 26.</citation>
    <PMID>25072780</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma Diffuse</keyword>
  <keyword>B-Cell lymphoma</keyword>
  <keyword>Aggressive lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

